Clinical Trials List
Protocol NumberAC-203-EBS-007
Active
2023-12-01 - 2027-08-31
Phase II/III
Recruiting1
ICD-10Q81.0
Epidermolysis bullosa simplex
ICD-10Q81.1
Epidermolysis bullosa letalis
ICD-10Q81.2
Epidermolysis bullosa dystrophica
ICD-10Q81.8
Other epidermolysis bullosa
ICD-10Q81.9
Epidermolysis bullosa, unspecified
ICD-10Q82.8
Other specified congenital malformations of skin
ICD-10Q82.9
Congenital malformation of skin, unspecified
ICD-9757.39
Other specified anomalies of skin
-
Trial Applicant
TWI BIOTECHNOLOGY, INC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Wei-Ting Tu Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
7 participants
-
Global
100 participants
